Silo Pharma Inc (SILO) Stock Price, Quote & News

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders....

Industry: Biotechnology

Sector: Healthcare

Phone: 718 400 9031

Website: silopharma.com

Address:

677 North Washington Boulevard, Sarasota, United States

onestudy Aug. 16 at 2:15 PM

$SILO FDA Commissioner Marty Makary says exploring the potential of psychedelics is now a "top priority" for the Trump administration — particularly when it comes to helping military veterans with PTSD according to Marijuana Moment.

0 · Reply

onestudy Aug. 15 at 4:23 PM

$SILO Big momentum. Louisiana bill advancing to study psychedelics for vets. $SILO is awaiting PTSD drug dosing results (FDA) — due ≤4 weeks. Recently $SILO got engaged with U.S. Department of Veterans Affairs via $HOTH which already started a VA study.

0 · Reply

ka1954 Aug. 15 at 2:09 PM

$SILO u can fight a stock that goes 300% so easily every few months. go ahead and sell it. i will hold until i get my 200%+

0 · Reply

onestudy Aug. 15 at 1:15 AM

$SILO According to the latest earnings report filed on Aug. 13, 2025, $SILO has enough cash to fund operations for at least the next 12 months.

0 · Reply

PSM_EmpowerTrading Aug. 14 at 7:01 PM

⏳️⌛️ Potential swing ideas 💡 ✅️ $SILO recently acquired digital assets from MAVS holdings, have until 12/24/25 to regain Nasdaq compliance by bringing price above $1 for 10 consecutive days, recently partnered with $HOTH for obesity treatment, upcoming catalyst: 1) preclinical data on SPC-15, intranasal therapy (5-HT4 receptor agonist) aimed at PTSD and anxiety, leveraging a fast-acting nose-to-brain delivery mechanism in Q3, ✅️ $HOTH recently entered joint venture with $SILO Pharma to commercialize VA-invented obesity Drug, recent data demonstrated significant reduction in tumor growth, announced patent to develop anti-obesity treatments with US Depart. Of Veterans Affairs, also previously purchased up to $1M of $BTC.X as treasury reverse asset, upcoming catalysts: 1) IND filing for HT-KIT, which recently announced positive data, suppressing tumor growth in preclinical models, expected to submit early 2026, D. Boral capital price target $5, HC Wainwright price target $4

0 · Reply

onestudy Aug. 13 at 10:50 PM

$PBMWW The New York Times just published a feature on former Texas Governor & Trump Energy Secretary Rick Perry, who has now dedicated his efforts to promoting ibogaine — a powerful psychedelic drug showing promise for addiction recovery and mental health. Psyence Biomedical is one of the few biopharmaceutical companies manufacturing high-quality psychedelic ibogaine APIs, positioning itself as a key supplier in the emerging psychedelic therapeutics market. Also watch $SILO : consolidating in the .60s for a couple months now, looking primed to break into the .80s. 🚀🚀🚀🚀🚀

0 · Reply

smoketuna Aug. 13 at 5:33 PM

$SILO 85% with 🎯 TunaSignal.ai score! while price $0.68 - Catch the Big Movers Before They Break Out - Powered by AI

0 · Reply

onestudy Aug. 12 at 2:30 PM

$SILO Trump, RFK Jr., and the Department of Veterans Affairs are teaming up to bring psychedelic drug treatments to veterans. It makes sense why VA would need $SILO for its PTSD drug pipeline. 🚀🚀🚀🚀🚀

0 · Reply

onestudy Aug. 12 at 1:18 PM

$SILO Citi’s SILO holdings now up ~609% QoQ (about $10K total). Not huge, but interesting that $SILO is getting some attention from a big tute.

0 · Reply

DaBullRunner Aug. 11 at 7:52 PM

$ASST not only called this in the .60’s but I buy what I call👇💰💰💰💰💰💰 Now I’m calling $VCIG before they release the news any day now WATCH AND LEARN $NXXT $SILO $IOBT watching

2 · Reply

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Jul 16, 2025, 8:45 AM EDT - 4 weeks ago

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Jul 7, 2025, 8:15 AM EDT - 5 weeks ago

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Jun 25, 2025, 8:38 AM EDT - 7 weeks ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025, 8:27 AM EDT - 7 weeks ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

HOTH

Jun 11, 2025, 9:00 AM EDT - 2 months ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Jun 5, 2025, 9:15 AM EDT - 2 months ago

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

May 21, 2025, 8:55 AM EDT - 3 months ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

May 16, 2025, 4:15 PM EDT - 3 months ago

Silo Pharma Announces Closing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 3 months ago

Silo Pharma Announces Pricing of $2 Million Public Offering

May 14, 2025, 4:07 PM EDT - 3 months ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 14, 2025, 8:40 AM EDT - 3 months ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Apr 30, 2025, 8:11 AM EDT - 3 months ago

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Apr 28, 2025, 7:50 AM EDT - 3 months ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Mar 26, 2025, 8:40 AM EDT - 5 months ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Feb 26, 2025, 1:30 PM EST - 6 months ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 18, 2025, 8:50 AM EST - 6 months ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 11, 2025, 7:45 AM EST - 6 months ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Jan 22, 2025, 8:29 AM EST - 7 months ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 2, 2025, 8:45 AM EST - 8 months ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Dec 18, 2024, 7:35 AM EST - 8 months ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Nov 29, 2024, 8:05 AM EST - 9 months ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Nov 18, 2024, 8:40 AM EST - 9 months ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Oct 31, 2024, 8:35 AM EDT - 10 months ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Sep 10, 2024, 6:35 AM EDT - 1 year ago

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Aug 14, 2024, 2:30 PM EDT - 1 year ago

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Aug 7, 2024, 8:13 AM EDT - 1 year ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Jul 26, 2024, 8:20 AM EDT - 1 year ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Jul 22, 2024, 4:45 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 19, 2024, 8:01 AM EDT - 1 year ago

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 18, 2024, 12:44 PM EDT - 1 year ago

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Jul 18, 2024, 8:25 AM EDT - 1 year ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Jul 16, 2024, 10:50 AM EDT - 1 year ago

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Jul 16, 2024, 6:30 AM EDT - 1 year ago

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Jun 26, 2024, 8:50 AM EDT - 1 year ago

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Jun 7, 2024, 8:18 AM EDT - 1 year ago

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Jun 6, 2024, 4:50 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jun 4, 2024, 8:41 AM EDT - 1 year ago

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

May 21, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

May 14, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

Apr 23, 2024, 8:15 AM EDT - 1 year ago

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Apr 10, 2024, 8:11 AM EDT - 1 year ago

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic

Mar 18, 2024, 7:15 AM EDT - 1 year ago

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Feb 28, 2024, 8:25 AM EST - 1 year ago

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Feb 14, 2024, 8:45 AM EST - 1 year ago

Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Feb 1, 2024, 10:00 AM EST - 1 year ago

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Jan 24, 2024, 8:55 AM EST - 1 year ago

Silo Pharma Announces Positive Results in Alzheimer's Disease Study

Jan 4, 2024, 8:55 AM EST - 1 year ago

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Dec 28, 2023, 8:25 AM EST - 1 year ago

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Nov 21, 2023, 8:01 AM EST - 1 year ago

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

onestudy Aug. 16 at 2:15 PM

0 · Reply

onestudy Aug. 15 at 4:23 PM

0 · Reply

ka1954 Aug. 15 at 2:09 PM

$SILO u can fight a stock that goes 300% so easily every few months. go ahead and sell it. i will hold until i get my 200%+

0 · Reply

onestudy Aug. 15 at 1:15 AM

$SILO According to the latest earnings report filed on Aug. 13, 2025, $SILO has enough cash to fund operations for at least the next 12 months.

0 · Reply

PSM_EmpowerTrading Aug. 14 at 7:01 PM

0 · Reply

onestudy Aug. 13 at 10:50 PM

0 · Reply

smoketuna Aug. 13 at 5:33 PM

$SILO 85% with 🎯 TunaSignal.ai score! while price $0.68 - Catch the Big Movers Before They Break Out - Powered by AI

0 · Reply

onestudy Aug. 12 at 2:30 PM

0 · Reply

onestudy Aug. 12 at 1:18 PM

$SILO Citi’s SILO holdings now up ~609% QoQ (about $10K total). Not huge, but interesting that $SILO is getting some attention from a big tute.

0 · Reply

DaBullRunner Aug. 11 at 7:52 PM

$ASST not only called this in the .60’s but I buy what I call👇💰💰💰💰💰💰 Now I’m calling $VCIG before they release the news any day now WATCH AND LEARN $NXXT $SILO $IOBT watching

2 · Reply

FINTECFA Aug. 11 at 10:34 AM

$SILO

0 · Reply

SlamminSammmy Aug. 8 at 9:28 PM

$SILO this is a sleeping giant.

0 · Reply

ka1954 Aug. 8 at 8:10 PM

$SILO u guys sold because company announced they r holding money in crypto assets. so what? LOL. They r holding main stream crypto assets like bitcoin, ether solana, not some junk alt coins. this is bullish not bearish

0 · Reply

Baba200TradeBot Aug. 8 at 8:00 PM

lowfloatreport.com/ - $SILO 🌙 After hours prints slipped ‑5.7% to 0.65, but that move was carved out on just 310 shares—barely 0.005 % of the tiny 6.1 M float—so price is skating on glass and can gap violently once real liquidity shows up. 🚀 During the regular session 444 K shares changed hands, rotating ~7.3 % of the float (0.39 × its normal volume), which means most owners are still “fresh” and even a modest bid/ask imbalance at tomorrow’s bell could ignite a fast squeeze or rug: a single average-true-range of 0.07 already equals a 10 % swing. 📈 Keep an eye on pre-market prints— reclaiming today’s 0.70 HOD would trap late shorts (short float only 2.6 %, but the ratio is 0.14 so they’re trading, not investing), while a fade through 0.60 would open the door to fill the morning range at 0.61-0.62; headline tailwind is the newly announced crypto-treasury pivot, so watch volume first, narrative second. 🎯 Full data: LowFloatReport.com

0 · Reply

Lifefinder Aug. 8 at 7:45 PM

$SILO some thing is going to happen here soon ….

0 · Reply

onestudy Aug. 8 at 4:00 PM

$PBM I found that the Mississippi State Senate schedule lists a Public Health joint hearing on psychedelic ibogaine for Thursday, August 28, 2025, at 10:00 AM (Room 216). Led by Rep. Sam Creekmore (R), the hearing will consider allowing clinical trials for the psychedelic in treating serious mental health conditions — especially for military veterans with PTSD and addiction. Just last week, $PBM / $PBMWW announced a PR on producing purified psychedelic ibogaine via strategic partner PsyLabs. I’m also watching $SILO which is awaiting FDA feedback on its psychedelic-based PTSD drug. 🚀🚀🚀🚀🚀

3 · Reply

onestudy Aug. 8 at 11:44 AM

$SILO On August 4, 2025, $SILO officially launched its cryptocurrency strategy and appointed its first board member, Corwin Yu, with options to purchase 45,000 shares at $0.7757. The company plans to have three members on its Crypto Advisory Board when complete. 🚀🚀🚀🚀🚀

0 · Reply

onestudy Aug. 7 at 6:55 PM

$SILO Trump is moving to allow cryptos in 401(k)s, and CNBC confirms a major executive order is on the way. A huge crypto catalyst! If $SILO had released its crypto treasury strategy PR today, the stock might have already pushed over a dollar. Maybe. The company is still in the process of forming its crypto advisory board, so that part will take time. I’m not expecting them to suddenly come out and say they bought a million bitcoins. My focus remains on the FDA test result catalyst, which does have a set timeline. I'm also waiting to hear more about the obesity therapy study with the U.S. Department of Veterans Affairs, which reportedly began a couple of weeks ago, according to Hoth Therapeutics’ press release. 🚀🚀🚀🚀🚀

0 · Reply

onestudy Aug. 7 at 5:00 PM

$SILO was that a stop-loss attack and it doesn't work here

0 · Reply

onestudy Aug. 7 at 3:07 PM

$SILO AdvisorShares reported a 48.3% increase in its position in $SILO — a biotech working on psychedelic-based treatments for PTSD and Alzheimer’s, and currently awaiting FDA-requested dosing results for its drug. AdvisorShares Investments LLC manages $PSIL (Psychedelics ETF), $YOLO (Cannabis ETF), and $MSOS (U.S. Cannabis ETF). Also, PSIL the Psychedelics ETF includes shares of SILO.

0 · Reply

ka1954 Aug. 6 at 8:05 PM

$SILO why the discount, from .77 to .59? just because they r going to put their money in crypto like 100s of other companies r doing. or is it just an excuse to force some of u to sell ?

0 · Reply

onestudy Aug. 6 at 5:20 PM

$SILO I just found out that Hoth Therapeutics already started the obesity therapy study with the U.S. Department of Veterans Affairs in Atlanta. Remember the PR from June 25, 2025 — $SILO signed a 50:50 joint venture with $HOTH to co-develop this Department of Veterans Affairs / Emory University therapy for obesity. And YES, Emory University is in Atlanta. The next PR about this U.S. Department–backed obesity therapy project should come from $SILO. 🚀🚀🚀🚀🚀

0 · Reply

Market Cap	3.18M
Revenue (ttm)	70,000.00
Net Income (ttm)	-4.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,271.43%
Debt to Equity Ratio	0.00

Volume	371,200
Avg Vol	1,011,816
Day's Range	N/A - N/A
Shares Out	4.48M
Stochastic %K	88%
Beta	0.31
Analysts	Strong Sell
Price Target	$10.00